article thumbnail

Opinion: Compounding pharmacies offer a fix for shortages of essential drugs

STAT

At the urging of the Alliance for Pharmacy Compounding, the trade association I lead, the Food and Drug Administration in April 2020 issued temporary guidance allowing traditional compounding pharmacies, within tight regulatory guardrails, to prepare 13 Covid drugs from pure ingredients to meet hospitals’ urgent need.

article thumbnail

STAT+: Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news

STAT

The EU moved swiftly after the Covid pandemic emerged in 2020 to secure vaccines for member countries to buy for their citizens and residents, but many aspects of the procurement from Pfizer have been kept confidential, leading to claims of a lack of transparency and several legal proceedings.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Hims & Hers Health to introduce generic Liraglutide in 2025 amid growing demand for weight-loss medications

Express Pharma

It results in less weight loss on average than Novo’s newer in-demand Wegovy, which launched in 2020 and was approved in 2022 for adolescents aged 12 and older. Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month. regulations.

article thumbnail

Respiratory syncytial virus prophylactic market to surpass $6 bn across 8MM in 2030

Express Pharma

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM*) is forecast to grow at a compound annual growth rate (CAGR) of 26.7 per cent from $582 million in 2020 to $6.2 billion in 2030, with the pediatric and adult segments accounting for $2.2 billion and $4.0

Vaccines 102
article thumbnail

2020 review – Pharma’s progress outside of COVID-19

pharmaphorum

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”. Merck & Co is already a major player in immunotherapy with its Keytruda (pembrolizumab) and spent $2.75

article thumbnail

Approvals in the Crazy Year of 2020

Eye on FDA

During 2020, FDA was able to approve 53 – not surpassing the 2018 all time record of 59, but certainly an admirable second place. Notably, the 2020 NME approvals included 22 related to oncology, with 2 new GIST treatments, 3 in breast cancer and 2 approvals in prostate cancer. That, however, was not really the case.

article thumbnail

2020 OPDP Enforcement

Eye on FDA

Looking now to a review of enforcement by the Office of Prescription Drug Promotion (OPDP) in 2020, we see a different picture. The collection of letters issued by OPDP during 2020 can be found here. We instead see the same pace as we have the past several years – that is anemic levels of enforcement.